Responsible Ceremonial Medicine: A Review of Current Evidence, Safety Protocols, and Ethical Considerations for Professional Practice
Zenodo (CERN European Organization for Nuclear Research) April 3, 2026 Espinoza Patricio
Psilocybin and ayahuasca show promise as therapeutic agents for major depression and treatment-resistant depression, based on data from over 134 registered clinical trials and key publications in major medical journals. The therapeutic effects appear to involve psychedelic-induced neuroplasticity through BDNF receptor TrkB binding and DMT-regulated adult neurogenesis. Safety evidence comes from systematic reviews and established guidelines. The three-phase model (preparation, experience, integration) documented in leading clinical trials constitutes the minimum professional standard for responsible ceremonial medicine practice. Ethical and cultural considerations for professional practice involving plant-based psychedelic compounds are also addressed.